Αρχική World News First Mature Estimation of Median OS for Selpercatinib in Patients with RET... World News First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC Από Ogkologos - 12 Μαρτίου, 2025 927 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy... 8 Φεβρουαρίου, 2022 What to Know About Getting Access to New Cancer Advances Presented... 14 Σεπτεμβρίου, 2022 Your NCI: Top Priorities from AACR 2026 4 Μαΐου, 2026 Epigenetic Changes Pinpointed as the Cause of Some GISTs 19 Νοεμβρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma Boy Shaves Head To Support Friend Going Through Cancer Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer What is De-escalation Treatment in Cancer Research?